A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers

Start Date12 May 2026

Sponsor / Collaborator

Vicore Pharma AB

CTIS2025-520702-35-00

/ CompletedPhase 1

A randomised, open-label, 5-period, cross-over trial to assess the pharmacokinetics and safety of 3 oral solid formulations of buloxibutid (C21) in healthy male and female participants

Start Date14 May 2025

Sponsor / Collaborator

Vicore Pharma AB

NCT06588686

/ Active, not recruitingPhase 2

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis.

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.
Trial website: www.aspire-ipf.com

Start Date09 Dec 2024

Sponsor / Collaborator

Vicore Pharma AB

[+1]

100 Clinical Results associated with Buloxibutid

100 Translational Medicine associated with Buloxibutid

100 Patents (Medical) associated with Buloxibutid

241

Literatures (Medical) associated with Buloxibutid

02 Jan 2026·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis

Review

Author: Young, Olivia N. ; Bourke, Jane E. ; Widdop, Robert E.

INTRODUCTION:

Current standard-of-care for idiopathic pulmonary fibrosis is limited to nintedanib and pirfenidone, which only slow the progressive loss of lung function and have significant adverse effects that are intolerable to many patients. There is therefore a significant unmet need for alternative treatments for this incurable disease.

AREAS COVERED:

This review describes emerging evidence implicating dysregulation of the renin-angiotensin system in IPF pathogenesis, and both pre-clinical and recent clinical data supporting activation of the anti-fibrotic AT₂R as a promising therapeutic strategy. The efficacy of AT₂R agonists across pre-clinical models of both IPF and relevant lung diseases is discussed, with a particular focus on favorable findings with the AT₂R agonist C21 (buloxibutid), leading to its current clinical trials for IPF.

EXPERT OPINION:

Rapid translation of C21 (now named buloxibutid), the first-in-class orally available AT₂R agonist, to early phase clinical trials for IPF have established its safety and disease-modifying potential. Ongoing development of novel, more highly selective AT₂R agonists may deliver the same clinical benefit as C21 with reduced off-target effects. The AT₂R drug class offers great promise as novel therapeutics, potentially extending beyond IPF to other inflammatory and fibrotic lung diseases.

01 Dec 2025·Alzheimers & Dementia

Somatostatin interneuron inhibition as a strategy to restore excitation‐inhibition balance in Alzheimer's disease

Article

Author: Abdallah, Sarena ; Ndambakuwa, Wadzanai ; Algamal, Moustafa ; Bacskai, Brian J. ; Kastanenka, Ksenia V.

Abstract:

Background:

Alzheimer's disease (AD) is characterized by the accumulation of extracellular amyloid plaques, leading to aberrant neuronal activity and an imbalance between excitatory and inhibitory activity. This disruption contributes to network dysfunction and cognitive impairment in AD patients. Our previous work has demonstrated that excitatory neuron activity is reduced in APP/PS1 mice, while somatostatin (SOM) inhibitory interneuron activity is increased near amyloid plaques under isoflurane anesthesia. Given this imbalance, we hypothesized that inhibiting SOM interneurons could restore excitatory neuron activity and improve memory deficits in AD mouse models. To test this, we employed both acute and chronic chemogenetic approaches to manipulate SOM interneuron activity.

Methods:

We used in vivo calcium imaging in APP and wild‐type (WT) mice to evaluate excitatory neurons after acute chemogenetic inhibition of SOM interneurons. For chronic inhibition, we intravenously delivered AAVPHP.eB encoding chemogenetic receptors to achieve non‐invasive, brain‐wide inhibition of SOM interneurons in APP/PS1 and WT mice. We then administered C21 subcutaneously for 16 days, followed by behavioral assessments. Behavioral tests evaluated locomotion and memory consolidation.

Results:

Calcium imaging confirmed that the excitation‐inhibition (E/I) imbalance persists in awake APP mice, demonstrating increased SOM interneuron activity and decreased excitatory neuron activity, mirroring our findings under anesthesia.Acute chemogenetic inhibition of SOM interneurons successfully enhanced excitatory neuron activity, supporting the hypothesis that reducing SOM interneuron activity can restore E/I balance in APP/PS1 mice. However, chronic inhibition of SOM interneurons failed to restore behavioral deficits in APP/PS1 mice, as no significant differences were observed in locomotor activity, working memory, or fear memory acquisition and recall in APP/PS1 or WT mice.

Conclusion:

While acute inhibition of SOM interneurons can restore excitatory neuron activity, brain‐wide chronic inhibition does not effectively improve memory function in APP/PS1 mice under the current experimental conditions.

01 Oct 2025·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Exploring spirocyclic isoquinoline-piperidine compounds in tuberculosis therapy: ADMET profiling, docking, DFT, MD simulations, and MMGBSA analysis

Article

Author: Enneiymy, Mohamed ; Nanduri, Srinivas ; Singampalli, Anuradha ; Yaddanapudi, Venkata Madhavi ; Singothu, Siva ; Bellapukonda, Sri Mounika ; Bandela, Rani ; Kumar, Pardeep ; Bhandari, Vasundhra ; AlAjm, Mohamed F ; Oubella, Ali

Tuberculosis remains a global health challenge due to drug-resistant strains. MmpL3 inhibitors have emerged as promising anti-tubercular agents, and their clinical development has been hindered by poor microsomal stability. This study computationally designed and screened 40 spirocyclic analogs, and compared them with ICA38 and SQ109. In silico analyses, including docking, MD simulations, and DFT calculations, were conducted to assess their potential as anti-tubercular agents, highlighting promising candidates for further development. Docking studies using Glide software identified C21 (3,4- dichloro derivative) and C20 (5-chloro derivative) as promising candidates, exhibiting binding scores of -9.79 kcal/mol and -9.64 kcal/mol, respectively. Both compounds interacted with the active site residue Asp645 via hydrogen bonding and also formed a hydrophobic interaction. DFT results revealed that C21 displayed the balanced chemical reactivity, characterized by high dipole moment (3.63D), an optimal energy gap (0.18752 eV), softness and hardness (η = 0.09376 eV, σ = 10.666 eV⁻¹), high electron affinity (0.02305 eV), high electronegativity (0.11681 eV) and high ionization potential (0.21057 cV). On the other hand, C20 exhibited similar electronic properties with marginal differences than C21. MD simulations showed C21 and C20's stability (RMSD 2.4 Å and 2.2 Å, RMSF <2.5 Å), indicating improved Arg344-Leu354 stability. Additionally, C21 and C20 maintained Asp645 interactions (91 %, 97 %) and showed strong binding with free energy values (MMGBSA: -72.23, -66.50 kcal/mol). These findings highlight the efficiency of the compounds C21 and C20 with strong binding affinity, favorable stability, and optimal electronic properties, making them promising candidates for further development of next-generation MmpL3 inhibitors.

News (Medical) associated with Buloxibutid

23 hours ago

·www.biospace.com

Vicore Pharma Elects Peter Guenter to its Board of Directors

Appointment strengthens Vicore's board with nearly four decades of global pharmaceutical leadership as the company advances buloxibutid toward an important late-stage data readout STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Peter Guenter has been elected as a new member of the Board of Directors. Peter Guenter brings nearly four decades of leadership experience in the global pharmaceutical industry, including roles as Chief Executive Officer at two major European pharmaceutical companies. Most recently, he served as CEO of Merck Healthcare KGaA, following his tenure as CEO of Almirall from 2017 to 2020, where he led a successful strategic refocus on medical dermatology. Before his time at Almirall, Mr. Guenter spent more than 20 years at Sanofi, where he held numerous senior leadership roles of increasing responsibility. He joined Sanofi's Executive Committee in 2013 as Executive Vice President for Global Commercial Operations. Beyond his executive roles, Mr. Guenter is a board member of Ipsen and an industry advisor to private equity firms. "We are delighted to welcome Peter to the Vicore board," said Hans Schikan, Chairman of the Board of Vicore Pharma. "His exceptional track record leading major pharmaceutical companies at the CEO level, combined with his deep commercial and strategic expertise, makes him an outstanding addition to our board at this exciting and consequential stage of Vicore's development. As we advance buloxibutid toward a topline data readout in mid-2027, Peter's experience in building portfolios and executing late-stage development and commercialization strategies will be invaluable." "Peter's appointment is a strong signal of the quality of the opportunity Vicore represents," said Ahmed Mousa, CEO of Vicore Pharma. "Having led transformational efforts at some of the world's most respected pharmaceutical companies, he brings precisely the perspective and expertise we need as we move closer to this important data readout for buloxibutid in IPF, a disease with substantial unmet need. I look forward to working closely with Peter." "I am excited to join the Vicore board at such a pivotal moment for the company," said Peter Guenter. "Buloxibutid represents a genuinely differentiated approach in IPF, a disease where patients urgently need new treatment options. Vicore has built strong scientific, clinical, and operational foundations, and I look forward to contributing to the board's work as the company pursues its mission of delivering a potentially transformational therapy to patients." For more information, please contact: Megan Richards, VP, IR & Comms, +1 978 269 4372, megan.richards@vicorepharma.com Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. Attachments Vicore Pharma Elects Peter Guenter to its Board of Directors SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire

29 Apr 2026

·www.biospace.com

Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference

STOCKHOLM, SE / ACCESS Newswire / April 29, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present multiple posters at the 2026 American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida from May 15 - May 20, 2026. The abstracts include analyses from the completed Phase 2a AIR trial in idiopathic pulmonary fibrosis (IPF), as well as translational research exploring the biological pathways associated with angiotensin II type 2 (AT2) receptor activation. Buloxibutid's Efficacy in the Phase 2a AIR IPF Trial: Comparative Analysis of Baseline Characteristics of Indian Versus World Cohorts This analysis evaluates baseline clinical and imaging characteristics of patients included in the Phase 2a AIR trial, comparing patients recruited in India with an external global IPF dataset. The analysis explores demographic, physiological, and high-resolution CT-derived imaging features to assess comparability across regions. Poster Discussion Session C103: The Next Frontier of Therapy in Pulmonary Fibrosis Date: Tuesday, May 19, 2026 Time: 2:15 PM ET Location: West F3 (Level II, OCCC West Concourse) Buloxibutid Stabilizes and Improves Lung Function in Idiopathic Pulmonary Fibrosis and Elevates Plasma MMP-13, Linking AT2 Receptor Activation in Alveolar Epithelial Type 2 Cells to Resolution of Fibrosis This poster integrates findings from the 36‑week Phase 2a AIR trial with mechanistic preclinical analyses to explore biological pathways associated with AT2 receptor activation. The work examines changes in plasma matrix metalloproteinase‑13 (MMP‑13) in patients with IPF treated with buloxibutid, alongside cellular expression patterns in lung tissue from healthy and bleomycin‑treated rats elucidating the role of the AT2 receptor activation in epithelial cell-related processes in pulmonary fibrosis. Poster Discussion Session A110: Closing the Gap: Advances in Pulmonary Fibrosis Date: Sunday, May 17, 2026 Time: 2:15 PM ET Location: West F3 (Level II, OCCC West Concourse) Microvascular Normalization and Fibrosis Regression by the Angiotensin II Type 2 Receptor Agonist Buloxibutid in Pulmonary Hypertension Associated with Interstitial Lung Disease This poster presents preclinical research evaluating the effects of buloxibutid in the Sugen‑Hypoxia (SuHx) rat model, which is relevant to pulmonary hypertension and fibrotic lung disease. The study examines changes in pulmonary blood vessels and lung fibrosis following treatment with buloxibutid to examine the potential of AT2 receptor agonism in both pulmonary hypertension and IPF. Poster Discussion Session D109: Novel Insights into Pulmonary Vascular Diseases Date: Wednesday, May 20, 2026 Time: 11:00 AM ET Location: W414AB (Level IV, OCCC West Concourse) Following the presentations, each poster will be available on the Publications page of Vicore's website at In addition, Vicore has been selected to present at the ATS 2026 Respiratory Innovation Summit, a meeting attracting representatives from pharma business development, venture capital, government, academia, and clinical medicine, on May 16, 2026. For more information, please contact: Megan Richards, VP, IR & Comms, +1 978 269 4372, megan.richards@vicorepharma.com Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. Attachments Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire

Phase 2Fast TrackOrphan Drug

22 Apr 2026

·www.biospace.com

Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis

The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagement ASPIRE is designed to assess the effect of buloxibutid on forced vital capacity (FVC) over 52 weeks, the regulatory endpoint for idiopathic pulmonary fibrosis (IPF) Topline results are expected in mid-2027, supported by cash runway into the second half of 2028 STOCKHOLM, SE / ACCESS Newswire / April 22, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced completion of enrollment in the global Phase 2b ASPIRE trial evaluating buloxibutid for the treatment of IPF. The ASPIRE trial successfully enrolled more than 360 patients across over 100 sites in 14 countries, including 29 sites in the United States. Full trial enrollment was achieved earlier than anticipated, reflecting strong interest in buloxibutid and efficient trial execution. "Completing enrollment in ASPIRE represents an important milestone for Vicore and the buloxibutid program," said Ahmed Mousa, Chief Executive Officer of Vicore. "We are encouraged by the excellent collaboration with dedicated sites and the high level of interest from investigators and patients globally, which enabled efficient recruitment ahead of our expectations. This level of engagement reflects both the significant unmet need in IPF and the desire for new therapies. With enrollment complete, our focus is on continued disciplined execution as we advance toward a topline data readout in mid-2027." IPF remains a progressive and fatal lung disease with significant unmet medical need. Currently approved therapies have been shown to slow lung function decline, but the magnitude of benefit is limited, and treatment is frequently associated with tolerability challenges, underscoring the need for additional therapeutic options. "IPF remains a serious and progressive disease with limited treatment options," said Toby Maher, MD, PhD, Professor of Clinical Medicine and Director of Interstitial Lung Disease at Keck Medicine of Southern California. "With enrollment in ASPIRE complete, I'm looking forward to the trial's results and continue to be optimistic about buloxibutid's potential to help address this persistent unmet medical need." ASPIRE is a randomized, placebo-controlled, 52-week Phase 2b trial evaluating two doses of buloxibutid both as monotherapy and on top of background standard of care. The trial will measure the impact of buloxibutid on FVC over the 52-week treatment period, the regulatory endpoint for IPF. ASPIRE builds on encouraging results from Vicore's Phase 2a AIR trial in which buloxibutid treatment was associated with an improvement in FVC over 36 weeks. Vicore expects to report topline results from ASPIRE in mid-2027 and is well positioned to execute the program with cash runway extending into the second half of 2028. Vicore sincerely thanks the patients participating in the ASPIRE trial, as well as their families and caregivers, and the investigators, study staff, and clinical trial sites whose commitment and collaboration made this milestone possible. For more information, please contact: Megan Richards, VP, IR & Comms, +1 978 269 4372, megan.richards@vicorepharma.com Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. About Idiopathic Pulmonary Fibrosis (IPF) IPF is a progressive fibrotic lung disease, impacting approximately 3 million people globally. The average life expectancy following diagnosis is 3-5 years, and currently approved therapies offer only modest slowing of disease progression. While there are three anti-fibrotic therapies available today, a large proportion of patients do not initiate treatment, and those who do often discontinue due to limited efficacy and significant tolerability issues. With a growing patient population, there is a clear need for new treatments. About the Phase 2b ASPIRE Trial ASPIRE (NCT06588686) is a global 52-week Phase 2b, randomized, double-blind, placebo-controlled clinical trial designed to assess the efficacy and safety of buloxibutid in IPF patients who are either not currently on treatment or receiving background standard of care. Participants are randomized to receive one of two doses of buloxibutid (100 mg or 50 mg taken orally twice daily) or placebo. The primary endpoint is change from baseline in forced vital capacity (FVC) at 52 weeks, the registrational endpoint for IPF. Secondary endpoints include safety, tolerability, and the proportion of patients with disease progression over the trial period. The trial enrolled over 360 patients from more than 100 sites across 14 countries, including the United States. Attachments Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire

Phase 2Fast TrackOrphan Drug

100 Deals associated with Buloxibutid

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	United States	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	Argentina	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	Brazil	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	Colombia	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	Czechia	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	India	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	Philippines	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	Russia	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	South Africa	Vicore Pharma AB	16 Sep 2021
COVID-19	Phase 3	Ukraine	Vicore Pharma AB	16 Sep 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04533022 (AIR, CTgov)	Phase 2	Idiopathic Pulmonary Fibrosis	52	C21 (C21 100 mg BID, SAS)	dxwfzrhzaa = ygtdwkosrj wjbpnemodu (jzntunppmy, kqqrcmruob - thzzgwdphb) View more	-	23 May 2025
				C21 (C21 100 mg BID)	ohwjbbrrem(sdgahfjfwh) = nicnlxtxkk degqoggmix (tuovycvkpc, apovhjyktn - xmvesbthsr) View more
NCT05277922 (CTgov)	Phase 1	-	5	C21 (C21 3 ug/Min)	nfugcsrire(stxacehpfh) = fadnpxpndo meyheazkrw (oxdrnithak, 24.3) View more	-	23 Apr 2025
				C21 (C21 10 ug/Min)	nfugcsrire(stxacehpfh) = qdeknssuws meyheazkrw (oxdrnithak, 5.5) View more
NCT05831644 (CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Endothelial dysfunction	11	C21 (C21 Treatment)	cluijzfnmg(jnbvchsedf) = pffxbayecl iwxunkbkcl (sllzlxirga, 0.062) View more	-	12 Nov 2024
				placebo (Placebo Treatment)	cluijzfnmg(jnbvchsedf) = zwsfjsgkna iwxunkbkcl (sllzlxirga, 0.062) View more
NCT04533022 (AIR, ATS2024) Manual	Phase 2	Idiopathic Pulmonary Fibrosis	46	Buloxibutid	slgjtqfgmg(qcddpjajji) = bgnuhutupa fyvargqxsc (sxrbusqpom, -150 to +50) View more	Positive	29 Apr 2024
NCT04880642 (ATTRACT-3, CTgov)	Phase 3	COVID-19	272	C21 (C21 Treatment)	pkpwuayybv = tfxvfqfwsj todfffbjyv (vhedofhqtc, yseeydcyjn - zcziloulsu) View more	-	14 Dec 2023
				placebo (Placebo Treatment)	pkpwuayybv = mmyisioejj todfffbjyv (vhedofhqtc, wrdcykshlm - hkxzgquwxq) View more
ATS2023	Not Applicable	Idiopathic Pulmonary Fibrosis	-	C21 100 mg twice daily	jgvguofxlv(hkmalhsivq) = 3 SAE's none of which were treatment related inclusive of 1 death (COVID-19) bdxbxlnlzy (dlhckipvut ) View more	-	21 May 2023
NCT04388176 (CTgov)	Phase 2	Raynaud Disease \| Scleroderma, Systemic	20	placebo (Placebo)	oiwqgytlro(ramweryexa) = qfdqjbchsh rgulfdprex (lfwpdarmxw, 4.36) View more	-	18 May 2023
				C21 (C21 200 mg)	oiwqgytlro(ramweryexa) = grftifqatj rgulfdprex (lfwpdarmxw, 7.68) View more
NCT04533022 (AIR, Corporate Publications) Manual	Phase 2	Idiopathic Pulmonary Fibrosis	45	C21	obovywnwki(dpgkjrzxgj) = jmlbldpkee ebbynjpfzq (ujrfbvwsvy ) View more	Positive	05 Nov 2022
NCT04533022 (AIR, ERS2022)	Phase 2	Idiopathic Pulmonary Fibrosis	21	C21 100 mg	bilaxhwtil(cujxlwjdrw) = no signals of gastro-intestinal toxicity mcamdubmln (nkbjcqkgot ) View more	Positive	04 Sep 2022
NCT04452435 (ATTRACT, ESC2022)	Phase 2	COVID-19 NT-proBNP	206	C21	tjbzxspzxk(bmqukglwxq) = gsrlkuqnjx vzndlackir (wxtqvzzmqa )	-	29 Aug 2022
				Placebo	tjbzxspzxk(bmqukglwxq) = ywpslstxna vzndlackir (wxtqvzzmqa )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Buloxibutid

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation